

Appendix 4E and Preliminary Final Report

Year Ended 30 June 2023

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM



Chimeric Therapeutics Limited

Appendix 4E

Preliminary Final Report

Year ended 30 June 2023

Name of entity:	Chimeric Therapeutics Limited
ABN:	68 638 835 828
Year ended:	30 June 2023
Previous year:	30 June 2022

Results for announcement to the market

									\$
Revenue for ordinary activities	-	-%	to	-					
Loss from ordinary activities after tax attributable to members	Up	(60.4)%	to	(25,500,384)					
Net loss for the year attributable to members	Up	(60.4)%	to	(25,500,384)					

Distributions

No dividends have been paid or declared by the group for the current financial year. No dividends were paid for the previous financial year.

Explanation of results

The group reported a loss for the year ended 30 June 2023 of \$25,500,384 (30 June 2022: \$15,898,400). The increased loss largely relates to research and development and employment expenditure to progress the group's clinical trial and research activities.

At 30 June 2023 the group's net assets were \$6,077,222 (30 June 2022: 25,706,308) with cash reserves of \$2,362,654 (30 June 2022: \$18,381,533).

On 23 June 2023 the group announced that it had completed a \$1.5m Share Purchase Plan and entered into a share purchase agreement with Lind to provide initial funding of \$3.1m and total funding of up to \$10.1m.

On 3 July 2023, the initial funding of \$3.1m from Lind Global Fund II that is disclosed as cash in transit in the financial statements was received.

The Appendix 4E financial report follows, with the further details to be included in the audited financial statements to be released by 30 September 2023.

Net tangible assets per security

	2023 Cents	2022 Cents
Net tangible asset backing (per security)	(1.36)	3.04

Changes in controlled entities

There have been no changes in controlled entities during the year ended 30 June 2023.

Other information required by Listing Rule 4.3A

- | | |
|--|-----|
| a. Details of individual and total dividends or distributions and dividend or distribution payments: | N/A |
| b. Details of any dividend or distribution reinvestment plans: | N/A |
| c. Details of associates and joint venture entities: | N/A |
| d. Other information | N/A |

Audit

The financial statements are currently in the process of being audited. Audited financial statements along with the independent auditor report for the year end 30 June 2023 is expected to be released by the end of September 2023 with an unqualified opinion with a material uncertainty related to going concern.

Chimeric Therapeutics Limited

ABN 68 638 835 828

Preliminary Final Report - 30 June 2023

Financial statements	
Consolidated statement of profit or loss and other comprehensive income	2
Consolidated statement of financial position	3
Consolidated statement of changes in equity	4
Consolidated statement of cash flows	5
Notes to the financial statements	6

This financial statements are consolidated financial statements for the group consisting of Chimeric Therapeutics Limited and its subsidiaries. A list of subsidiaries is included in note 12.

The financial statements are presented in the Australian currency.

Chimeric Therapeutics Limited is a company limited by shares, incorporated and domiciled in Australia.

Its registered office is:

Level 3, 62 Lygon Street
Carlton VIC 3053

Chimeric Therapeutics Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2023

	Notes	30 June 2023 \$	30 June 2022 \$
Other income	1(a)	4,922,235	2,617,122
Other losses		(96,320)	(534,953)
General and administrative expenses	1(c)	(11,733,007)	(7,904,654)
Research and development expenses	1(c)	(14,432,338)	(6,115,990)
Share-based payments expenses		(3,321,854)	(3,169,055)
Operating loss		<u>(24,661,284)</u>	<u>(15,107,530)</u>
Finance income	1(d)	27,565	12,977
Finance expenses	1(d)	(773,845)	(640,127)
Finance costs - net		<u>(746,280)</u>	<u>(627,150)</u>
Loss before income tax		(25,407,564)	(15,734,680)
Income tax expense		(92,820)	(163,720)
Loss for the year		<u>(25,500,384)</u>	<u>(15,898,400)</u>
Other comprehensive loss			
<i>Items that may be reclassified to profit or loss:</i>			
Foreign currency translation		(151,399)	(153,788)
Total comprehensive loss for the year		<u>(25,651,783)</u>	<u>(16,052,188)</u>
		Cents	Cents
Loss per share for loss attributable to the ordinary equity holders of the group:			
Basic and diluted loss per share	11	(5.89)	(4.42)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Chimeric Therapeutics Limited
Consolidated statement of financial position
As at 30 June 2023

	Notes	2023 \$	2022 \$
ASSETS			
Current assets			
Cash and cash equivalents	2(a)	2,362,654	18,381,533
Trade and other receivables	2(b)	7,074,637	2,657,763
Other current assets		30,568	131,415
Total current assets		9,467,859	21,170,711
Non-current assets			
Property, plant and equipment		5,600	15,988
Intangible assets	3(a)	12,978,631	13,653,040
Other financial assets at amortised cost		40,000	40,000
Total non-current assets		13,024,231	13,709,028
Total assets		22,492,090	34,879,739
LIABILITIES			
Current liabilities			
Trade and other payables	2(c)	10,812,516	6,373,715
Other financial liabilities	2(d)	3,140,672	2,453,186
Employee benefit obligations	3(b)	439,341	193,960
Total current liabilities		14,392,529	9,020,861
Non-current liabilities			
Trade and other payables	2(c)	-	152,570
Other financial liabilities	2(d)	2,022,339	-
Total non-current liabilities		2,022,339	152,570
Total liabilities		16,414,868	9,173,431
Net assets		6,077,222	25,706,308
EQUITY			
Share capital	4(a)	53,929,488	51,807,595
Other reserves	4(b)	8,512,042	4,762,637
Accumulated losses		(56,364,308)	(30,863,924)
Total equity		6,077,222	25,706,308

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

Chimeric Therapeutics Limited
Consolidated statement of changes in equity
For the year ended 30 June 2023

Notes	Attributable to owners of Chimeric Therapeutics Limited			Total equity \$
	Share capital \$	Other reserves \$	Accumulated losses \$	
Balance at 1 July 2021	37,366,641	2,941,766	(15,177,719)	25,130,688
Loss for the year	-	-	(15,898,400)	(15,898,400)
Other comprehensive income	-	(153,788)	-	(153,788)
Total comprehensive loss for the year	-	(153,788)	(15,898,400)	(16,052,188)
Transactions with owners in their capacity as owners:				
Contributions of equity net of transaction costs	4(a) 13,081,054	-	-	13,081,054
Employee share schemes - value of employee services	4(b) 786,492	(84,960)	-	701,532
Options issued	4(b) 12,692	2,744,318	-	2,757,010
Issue of shares as part of forfeiture payments	4(b) 560,716	(196,409)	-	364,307
Issue of restricted share units	-	11,001	-	11,001
Forfeiture of options	-	(499,291)	212,195	(287,096)
	14,440,954	1,974,659	212,195	16,627,808
Balance at 30 June 2022	51,807,595	4,762,637	(30,863,924)	25,706,308
Balance at 1 July 2022	51,807,595	4,762,637	(30,863,924)	25,706,308
Loss for the year	-	-	(25,500,384)	(25,500,384)
Other comprehensive loss	-	(151,399)	-	(151,399)
Total comprehensive loss for the year	-	(151,399)	(25,500,384)	(25,651,783)
Transactions with owners in their capacity as owners:				
Contributions of equity	4(a) 1,532,497	-	-	1,532,497
Transaction costs and tax	4(a) (640,586)	-	-	(640,586)
Issue of shares in lieu of payment of services	4(a) 65,000	-	-	65,000
Options issued	4(b) -	3,095,864	-	3,095,864
Issue of shares as part of forfeiture payments	4(b) 293,729	(106,284)	-	187,445
Issue of restricted share units	4(b) -	(11,001)	-	(11,001)
Issue of shares under the employee incentive scheme	4(a) 871,253	(122,775)	-	748,478
Shares to be issued per board and management placement	4(a) -	1,045,000	-	1,045,000
	2,121,893	3,900,804	-	6,022,697
Balance at 30 June 2023	53,929,488	8,512,042	(56,364,308)	6,077,222

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Chimeric Therapeutics Limited
Consolidated statement of cash flows
For the year ended 30 June 2023

	30 June 2023	30 June 2022
Notes	\$	\$
Cash flows from operating activities		
Receipts from customers (inclusive of GST)	-	(16,395)
Payments to suppliers and employees (inclusive of GST)	(19,832,570)	(13,149,473)
Research and Development tax incentive received	3,499,252	-
Interest received	27,565	12,977
Net cash (outflow) from operating activities	(16,305,753)	(13,152,891)
Cash flows from investing activities		
Payments for financial assets at amortised cost	-	(40,000)
Payments for property, plant and equipment	-	(12,289)
Payments for intellectual property	(112,193)	(525,566)
Net cash (outflow) from investing activities	(112,193)	(577,855)
Cash flows from financing activities		
Proceeds from issues of shares and other equity securities	2,577,497	14,898,911
Share issue transaction costs	(88,819)	(1,308,664)
Interest expense	(10,302)	-
Repayment of financial liabilities	(2,225,000)	(4,046,819)
Net cash inflow from financing activities	253,376	9,543,428
Net (decrease) in cash and cash equivalents	(16,164,570)	(4,187,318)
Cash and cash equivalents at the beginning of the financial year	18,381,533	22,410,199
Effects of exchange rate changes on cash and cash equivalents	145,691	158,652
Cash and cash equivalents at end of year	2,362,654	18,381,533

At 30 June 2023 there was a difference between the above statement of cash flows and the Appendix 4C. Cash in transit of \$3.01m that was classified as cash and cash equivalents has since been recorded as trade and other receivables. This has resulted in a decrease of proceeds from issue of shares by \$3.1m and share issue transaction costs of \$93k. The cash was subsequently received by the group on 3 July 2023.

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

Contents of the notes to the financial statements

	Page
1 Other income and expense items	7
2 Financial assets and financial liabilities	10
3 Non-financial assets and liabilities	12
4 Equity	15
5 Critical estimates, judgements and errors	18
6 Contingent consideration	20
7 Commitments	22
8 Events occurring after the reporting year	23
9 Share-based payments	23
10 Remuneration of auditors	26
11 Loss per share	26
12 Interests in other entities	27

1 Other income and expense items

(a) Other income

	30 June 2023	30 June 2022
	\$	\$
Research and development tax incentive	4,922,235	2,617,122
	4,922,235	2,617,122

The group's research and development activities are eligible under an Australian government tax incentive for eligible expenditure. Where expenditure is incurred out with Australia, an 'overseas finding' must be obtained from AusIndustry prior to any such expenditure being eligible under the scheme. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2023, the group has included an item in other income of \$4,922,235 (2022: \$2,617,122) to recognise income over the period necessary to match the grant on a systematic basis with the costs that they are intended to compensate.

(b) Other losses

	30 June 2023	30 June 2022
	\$	\$
Net loss on disposal of property, plant and equipment	(2,448)	(2,065)
Net foreign exchange losses	(93,872)	(532,888)
	(96,320)	(534,953)

1 Other income and expense items (continued)

(c) Breakdown of expenses by nature

	30 June 2023	30 June 2022
	\$	\$
General and administrative expenses		
Accounting and audit	963,297	332,103
Consulting	87,924	182,517
Depreciation	7,941	7,866
Employee benefits	8,364,015	5,234,964
Insurance	378,411	262,768
Investor relations	455,168	387,967
Legal	393,799	419,036
Listing and share registry	166,414	178,759
Occupancy	25,868	13,710
Patent costs	185,583	84,574
Recruitment and staff training	212,689	313,347
Travel and entertainment	430,750	316,364
Other	61,148	170,679
	11,733,007	7,904,654
Research and development expenses		
Amortisation	957,410	941,896
Chlorotoxin CAR-T technology	4,790,033	2,348,152
CDH17	6,099,248	2,382,423
CORE-NK	39,567	-
Fair value movement in contingent consideration	1,614,334	-
Other	931,746	443,519
	14,432,338	6,115,990

The Research and Development expenses align with the intellectual property held by the group as disclosed in note 3 and represents the amount of R&D expended on developing the respective intellectual property.

1 Other income and expense items (continued)

(d) Finance income and Expenses

	30 June 2023	30 June 2022
	\$	\$
	Notes	
<i>Finance income</i>		
Interest income from financial assets held for cash management purposes	27,565	12,977
Finance income	27,565	12,977
<i>Finance Expenses</i>		
Interest and finance charges paid for financial liabilities not at fair value	(10,302)	-
Interest expense on acquisition of intangible assets	11,038	(640,127)
Finance Expenses in relation to financing activities	(774,581)	-
Finance Expenses	(773,845)	(640,127)
Net finance costs	(746,280)	(627,150)

2 Financial assets and financial liabilities

(a) Cash and cash equivalents

	2023	2022
	\$	\$
Current assets		
Cash at bank and on hand	<u>2,362,654</u>	<u>18,381,533</u>

(i) Reconciliation to cash flow statement

The above figures reconcile to the amount of cash shown in the consolidated statement of cash flows at the end of the financial year as follows:

	2023	2022
	\$	\$
Balances as above	<u>2,362,654</u>	<u>18,381,533</u>
Balances per statement of cash flows	<u>2,362,654</u>	<u>18,381,533</u>

(ii) Classification as cash equivalents

Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition and are repayable with 24 hours notice with no loss of interest.

(iii) Risk exposure

The maximum exposure to credit risk at the end of the reporting year is the carrying amount of each class of cash and cash equivalents mentioned above.

(b) Trade and other receivables

		2023			2022		
		Current	Non-current	Total	Current	Non-current	Total
Notes		\$	\$	\$	\$	\$	\$
Cash in transit	2(b)(i)	3,007,000	-	3,007,000	-	-	-
Trade receivables		26,622	-	26,622	40,573	-	40,573
Accrued receivables	2(b)(ii)	4,040,105	-	4,040,105	2,617,122	-	2,617,122
Other receivables		910	-	910	68	-	68
		<u>7,074,637</u>	<u>-</u>	<u>7,074,637</u>	<u>2,657,763</u>	<u>-</u>	<u>2,657,763</u>

(i) Cash in transit

Cash in transit relates to the initial funding of \$3.1m from Lind Global Fund II less the commitment fee of \$93,000. The initial funding was transferred from Lind Global Fund II on 30 June 2023 and was received on 3 July 2023.

(ii) Accrued receivables

Accrued receivables comprise \$4,040,105 from the Australian Taxation Office in relation to the R&D tax incentive (2022: \$2,617,122).

2 Financial assets and financial liabilities (continued)

(c) Trade and other payables

	2023			2022		
	Current	Non-current	Total	Current	Non-current	Total
	\$	\$	\$	\$	\$	\$
Trade payables	7,406,782	-	7,406,782	4,703,609	-	4,703,609
Amounts due to employees	258,301	-	258,301	289,414	152,570	441,984
Accrued expenses	3,069,002	-	3,069,002	1,346,899	-	1,346,899
Other payables	78,431	-	78,431	33,793	-	33,793
	10,812,516	-	10,812,516	6,373,715	152,570	6,526,285

(d) Other financial liabilities

	2023			2022		
	Current	Non-current	Total	Current	Non-current	Total
	\$	\$	\$	\$	\$	\$
Chlorotoxin CAR-T deferred consideration	-	1,454,763	1,454,763	2,177,384	-	2,177,384
CHD17 contingent consideration	-	467,823	467,823	275,802	-	275,802
CORE-NK contingent consideration	40,672	99,753	140,425	-	-	-
Lind share purchase agreement	3,100,000	-	3,100,000	-	-	-
	3,140,672	2,022,339	5,163,011	2,453,186	-	2,453,186

The deferred consideration relates to payable upfront costs from the acquisition of licences. During the year the group paid \$112,340 (2022: \$4,046,819) inclusive of deferred consideration liability. The contingent consideration includes amounts related to the provision of milestone payments. For more information, please refer to note 6.

3 Non-financial assets and liabilities

(a) Intangible assets

	Chlorotoxin CAR-T \$	CDH-17 \$	CORE-NK \$	Total \$
At 1 July 2021				
Cost	14,670,492	-	-	14,670,492
Accumulated amortisation and impairment	(844,327)	-	-	(844,327)
Net book amount	13,826,165	-	-	13,826,165
Year ended 30 June 2022				
Opening net book amount	13,826,165	-	-	13,826,165
Additions	-	719,863	48,908	768,771
Amortisation charge	(903,752)	(38,144)	-	(941,896)
Closing net book amount	12,922,413	681,719	48,908	13,653,040
At 30 June 2022				
Cost	14,670,492	719,863	48,908	15,439,263
Accumulated amortisation and impairment	(1,748,079)	(38,144)	-	(1,786,223)
Net book amount	12,922,413	681,719	48,908	13,653,040
Year ended 30 June 2023				
Opening net book amount	12,922,413	681,719	48,908	13,653,040
Additions	-	-	283,001	283,001
Amortisation charge	(903,752)	(40,473)	(13,185)	(957,410)
Closing net book amount	12,018,661	641,246	318,724	12,978,631
At 30 June 2023				
Cost	14,670,492	719,863	331,909	15,722,264
Accumulated amortisation and impairment	(2,651,831)	(78,617)	(13,185)	(2,743,633)
Net book amount	12,018,661	641,246	318,724	12,978,631

The group's intellectual property is measured at initial cost, less any accumulated amortisation and impairment losses.

(i) Chlorotoxin CAR-T technology

The company has recognised the Intellectual Property "Chlorotoxin CAR-T technology" through the acquisition of a worldwide exclusive licence developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California. The licence agreement between City of Hope and Chimeric is perpetual.

3 Non-financial assets and liabilities (continued)

(a) Intangible assets (continued)

(i) Chlorotoxin CAR-T technology (continued)

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amount recognised as an intangible asset relate to the upfront licences fee paid, the value of equity issued to City of Hope in respect of the licence agreement and contingent considerations. The contingent consideration arrangements require the group to pay City of Hope amounts based on the licence agreement upon completion of each milestone. The fair-value of the contingent considerations was probability adjusted based on the directors' assumption, 90% probability of completing milestone 1.

The Chlorotoxin CAR-T technology is amortised over a period of 16 years, being management's assessed useful life of the intangible asset.

(ii) CDH-17

The group has recognised the Intellectual Property "CDH17" through the acquisition of a worldwide exclusive licence developed at University of Pennsylvania, a world-renowned Cell Therapy Centre based in Philadelphia, Pennsylvania. The licence agreement between University of Pennsylvania and Chimeric is perpetual.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licenses fee paid and the value of equity issued to University of Pennsylvania in respect of the licence agreement.

CDH-17 is amortised over a period of 18 years, being management's assessed useful life of the intangible asset.

(iii) CORE-NK

The group has recognised the Intellectual Property "CORE-NK" through the acquisition of an exclusive licence developed at Case Western Reserve University, a private research university based in Cleveland, Ohio. The licence agreement between Case Western Reserve University and Chimeric is perpetual.

It is the board's expectation that the acquired intellectual property will generate future economic benefits for the group. The amounts recognised as intangible assets relate to the upfront licence fee paid and the value of equity issued to Case Western Reserve University in respect of the licence agreement.

CORE-NK is amortised over a period of 15 years, being management's assessed useful life of the intangible asset.

(iv) Impairment test for intellectual property

Intellectual property held by the group is assessed for indicators of impairment annually.

There were no indicators of impairment identified at 30 June 2023.

- The market capitalisation of Chimeric Therapeutics Limited on the Australian Securities Exchange is in excess of the net book value of assets;
- There have been no significant changes that have taken place during the year that have adversely affected the CAR-T sector or scientific results and progress of trials.

See note for the other accounting policies relevant to intangible assets, and note for the group's policy regarding impairments.

3 Non-financial assets and liabilities (continued)

(b) Employee benefit obligations

		2023		2022		
	Current	Non-current	Total	Current	Non-current	Total
	\$	\$	\$	\$	\$	\$
Leave obligations (i)	439,341	-	439,341	193,960	-	193,960

(i) Leave obligations

The leave obligations cover the group's liabilities for annual leave which are classified as short-term benefits.

The current portion of this liability includes all of the accrued annual leave and pro-rata payments employees are entitled to in certain circumstances. The entire amount of the provision of \$439,341 (2022: \$193,960) is presented as current, since the group does not have an unconditional right to defer settlement for any of these obligations. However, based on past experience, the group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months.

4 Equity

(a) Share capital

	Notes	2023 Shares	2022 Shares	2023 \$	2022 \$
Ordinary shares					
Fully paid					
	4(a)(i)	506,685,568	425,278,237	53,929,488	51,807,595
		506,685,568	425,278,237	53,929,488	51,807,595

(i) Movements in ordinary shares:

Details	Number of shares	Total \$
Balance at 1 July 2021	330,859,716	37,366,641
Issue of shares under the employee incentive scheme at \$0.29 (2021-08-27)	1,575,072	456,771
Issue of shares under the employee incentive scheme at \$0.309 (2021-08-27)	630,890	194,945
Issue of shares under the employee incentive scheme at \$0.287 (2021-08-27)	377,810	108,431
Issue of forfeiture shares at \$0.272 (2021-12-03)	2,064,832	560,716
Issue of shares under the employee incentive scheme at \$0.276 (2021-12-06)	95,330	26,344
Issue at \$0.17 pursuant to institutional offer (2022-02-28)	43,339,291	7,367,680
Issue at \$0.17 pursuant to entitlement offer (2022-03-25 to 30)	41,285,524	7,018,539
Issue at \$0.10 pursuant to entitlement offer (2022-06-15)	5,000,000	500,000
Issue at \$0.255 on exercise of listed options (2022-06-29)	49,772	12,692
Less: Transaction costs arising on share issues	-	(1,805,164)
Balance at 30 June 2022	425,278,237	51,807,595
Balance at 1 July 2022	425,278,237	51,807,595
Issue of shares under the employee incentive scheme at \$0.259 (2022-11-18)	132,829	34,403
Issue of shares under the employee incentive scheme at \$0.091 (2022-11-18)	400,347	36,432
Issue of shares under the employee incentive scheme at \$0.151 (2022-11-18)	587,025	88,641
Issue of shares under the employee incentive scheme at \$0.232 (2022-11-18)	230,549	53,487
Issue of shares under the employee incentive scheme at \$0.092 (2022-11-18)	7,075,512	650,947
Issue of forfeiture shares at \$0.089 (2022-12-12)	3,300,325	293,729
Issue of shares under the employee incentive scheme at \$0.082 (2022-12-22)	89,551	7,343
Issue of shares from Share Purchase Plan at \$0.035 (2023-06-23)	43,785,637	1,532,497
Issue of shares upon termination of placement agreement at \$0.036 (2023-06-23)	1,805,556	65,000
Issue of Shares under the share purchase agreement at \$0.033 (2023-06-29)	24,000,000	-
Less: Transaction costs arising on share issues	-	(640,586)
Balance 30 June 2023	506,685,568	53,929,488

4 Equity (continued)

(b) Other reserves

The following table shows a breakdown of the Statement of financial position line item 'other reserves' and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table.

Notes	Shares to be issued \$	Share- based payments \$	Equity settled payments \$	Foreign currency translation \$	Total other reserves \$
At 1 July 2021	-	2,337,660	611,744	(7,638)	2,941,766
Currency translation differences	-	-	-	(153,788)	(153,788)
Other comprehensive income	-	-	-	(153,788)	(153,788)
Transactions with owners in their capacity as owners					
Issue of options	-	2,744,318	-	-	2,744,318
Issue of shares as part of forfeiture payments	-	-	(515,919)	-	(515,919)
Provision of forfeiture share payments	-	-	319,510	-	319,510
Issue of restricted share units	-	11,001	-	-	11,001
Share-based payment expenses	-	(84,960)	-	-	(84,960)
Forfeited options	-	(499,291)	-	-	(499,291)
At 30 June 2022	-	4,508,728	415,335	(161,426)	4,762,637
Currency translation differences	-	-	-	(151,399)	(151,399)
Other comprehensive income/loss	-	-	-	(151,399)	(151,399)
Transactions with owners in their capacity as owners					
Employee share schemes - value of employee services	36,900	(159,675)	-	-	(122,775)
Issue of options	-	3,095,864	-	-	3,095,864
Issue of shares as part of forfeiture payments	-	-	(106,284)	-	(106,284)
Issue of restricted share units	-	(11,001)	-	-	(11,001)
Shares to be issued per board and management placement	1,045,000	-	-	-	1,045,000
At 30 June 2023	1,081,900	7,433,916	309,051	(312,825)	8,512,042

(i) Nature and purpose of other reserves

Share-based payments

The share-based payment reserve records items recognised as expenses on valuation of share options and warrants issued to key management personnel, other employees and eligible contractors.

Foreign currency translations

Exchange differences arising on translation of foreign controlled entities are recognised in other comprehensive income or loss as described in note and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

4 Equity (continued)

(b) Other reserves (continued)

(i) *Nature and purpose of other reserves (continued)*

Equity settled payments

Equity settled payments reserve records items recognised as expenses on valuation of shares to be issued to key management personnel and other employees for forfeiture of long term incentives at previous employers.

(ii) *Movements in options:*

Details	Number of options	Total \$
Balance at 1 July 2021	26,463,453	2,093,025
Issue of Employee Stock Ownership Plan (ESOP) unlisted options	14,199,821	1,386,407
Issue of listed options	83,070,699	-
Issue of unlisted options	15,000,000	496,500
Forfeiture of ESOP unlisted options	(8,304,068)	(499,291)
Exercise of listed options	(49,772)	-
Expense for share-based payments for options previously issued	-	861,411
Balance at 30 June 2022	130,380,133	4,338,052
Issue of Employee Stock Ownership Plan (ESOP) unlisted options	28,613,089	1,179,574
Issue of unlisted options	4,500,000	82,350
Issue of options per share purchase agreement	41,891,892	681,581
Expense for share-based payments for options previously issued	-	1,152,359
Balance at 30 June 2023	205,385,114	7,433,916

5 Critical estimates, judgements and errors

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the group's accounting policies.

This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be wrong due to changes in estimates and judgements. Detailed information about each of these estimates and judgements is included in other notes together with information about the basis of calculation for each affected line item in the financial statements.

Estimates and judgements are continually evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the entity and that are believed to be reasonable under the circumstances.

The areas involving judgement or estimation are detailed below.

(a) Judgements

(i) Impairment

The group's intangible assets are assessed for impairment at each reporting period.

Management have not identified any indicators of impairment in the current year, for the following reasons:

- The market capitalisation of Chimeric Therapeutics Limited on the Australian Securities Exchange on the impairment testing date of 30 June 2023 is in excess of the net book value of assets;
- There have been positive scientific results and progress of trials;
- Comparisons with companies in a similar field of development and similar stage do not indicate any impairment;
- There has been positive growth in the biotech sector.

As no indicators of impairment have been identified, no impairment test has been performed. Should an indicator be identified, management would be required to perform an impairment test.

(b) Estimates

(i) R&D tax incentive income accrual

The group's research and development (R&D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured.

Judgement is applied to each transaction the group incurs each financial year, by determining a percentage of each transaction that relates to R&D.

R&D income is determined using eligibility criteria and percentages of eligibility estimated by management. These estimated eligibility percentages determine the base for which the R&D tax rebate is calculation and therefore is subject to a degree of uncertainty.

(ii) Useful life of intangible assets

Management have assessed that "ready for use" for the group is not the commercialisation of an intangible asset but rather the goal to develop intangible assets to a point that a trade sale of a licence is more likely. They have concluded that all intangible asset's are "ready for use" and have applied judgement over the period which each asset is expected to be available for use by the entity.

The maximum life in which the group has control of the intangible asset can be determined by the length of legal protection of the intellectual property (IP) covered by the patent life over the IP. The life of an asset is determined by reference to that IP protection, subject to reassessment each year, taking into consideration changing expectations about possible timing of trade sale of a licence.

5 Critical estimates, judgements and errors (continued)

(b) Estimates (continued)

(ii) Useful life of intangible assets (continued)

The useful life is determined using the expiry date of the last patent to expire. These dates determine the life of the IP and therefore is subject to a degree of uncertainty.

(iii) Share-based payments

The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions.

This model requires the following inputs which involve judgements to be made:

- Volatility rate is calculated by analysing the movement of the closing share price each day for the term of the option preceding grant date; and
- Risk-free rate is obtained by referencing to the Capital Market Yields for Government Bonds supplied by the RBA . The rate is selected by determining what the rate is at the date the options are granted to the holder. Additionally, there are different rates supplied by the RBA each day dependent on the terms of the bond (2, 3, 5, 10 years). The term of the option will determine which rate is used (i.e. a 5 year term will use the 5 year bond rate). If an options term is between two terms for example 4 years, the rate that is used is that of the lower term i.e. the 3 year bond rate.

These inputs determine the value of each share-based payment and therefore it is subject to a degree of uncertainty.

(iv) Contingent consideration

The fair value of the group's contingent consideration relating to the acquisition of licences is estimated using a present value technique which discounts the management's estimate of the probability that the milestone will be achieved. Management's assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters.

At the end of the reporting year, the group has applied judgement to multiple milestones detailed in note 6.

The probability assigned to each milestone determines the value of the consideration and therefore is subject to a degree of uncertainty.

The discount rate used at 30 June 2023 was 6.85% (2022: 4.52%). The discount rate is based on the expected rate of return, which has been determined using the capital asset pricing model.

The timeframe for discounting varies depending on the milestone, and is aligned with industry information on the length of time taken to conduct oncological clinical trials.

The fair value of contingent consideration is sensitive to changes in the probability of clinical trial success and the timeframe for completion of those clinical trials. These sensitivities are interdependent. A 1% change in the probability of clinical trial success or a 1 year reduction in the timeframe for completion of clinical trials would have a material impact on the fair value of contingent consideration.

6 Contingent consideration

(a) CAR-T technology intellectual property

The group has the licence agreement with the City of Hope. The key financial terms of the licence agreement includes cash payments worth US\$10 million. US\$4 million was paid in the year ending 30 June 2021, US\$3 million in the year ending 30 June 2022 and US\$1.5 million in the year ending 30 June 2023. The final payment of US\$1.5 million is due for payment in the year ending 30 June 2024. In addition, A\$1.6m worth of shares in the group were issued to the City of Hope as part of the agreement. The group has also incurred liabilities contingent on future events in respect of the licence, which are summarised below.

Management has determined the fair value of contingent consideration by assessing the probability of each milestone being achieved. Management's assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters.

The fair value is discounted as set out in note 5(b)(iv). The timeframe for discounting varies depending on the milestone, and is aligned with industry information on the length of time taken to conduct oncological clinical trials.

- **Development Milestone Payments:** Up to US\$17.1m payable to the City of Hope upon meeting various milestones:

Milestones	Requirements	Payment to City of Hope
1.	Dosing of fifth patient in the first Phase 1 Clinical Trial anywhere in the Territory	US\$0.35m
2.	Dosing of first patient in the first Phase 2 Clinical Trial anywhere in the Territory	US\$0.75m
3.	Dosing of first patient in the first Phase 3 Clinical Trial anywhere in the Territory	US\$2m
4.	Receipt of the first Orphan Drug Designation for each Licensed Product or Licensed Service	US\$1m
5.	Upon Marketing Approval in the United States	US\$6m
6.	Upon Marketing Approval in Europe	US\$6m
7.	Upon Marketing Approval in each of the first five jurisdictions other than the United States and Europe for each applicable Licensed Product or Licensed Service	US\$1m

As at 30 June 2023 only Milestone 1 has been achieved or paid (30 June 2022: only Milestone 1).

- **Sales Milestone Payments:** Within 30 days after the occurrence of each sales milestone set forth below with respect to each Licensed Product or Licensed Service that achieves such Sales Milestone Event, the Company is required to pay City of Hope the amount indicated below:

Milestones	Sales Milestone Event	Payment to City of Hope
1.	Upon Net Sales of Licenced Product or Licensed Service first totalling US\$250 million in a Licence Year	US\$18.75m
2.	Upon Net Sales of Licenced Product or Licensed Service first totalling US\$500 million in a Licence Year	US\$35.5m

(i) Royalties on net sales

The group is obliged to pay City of Hope royalties on net sales based on industry standard single digit royalty rates. This has no effect on the figures reported as at 30 June 2023 (30 June 2022: none.)

6 Contingent consideration (continued)

(b) CDH-17 intellectual property

The group has the licence agreement with University of Pennsylvania. The key financial terms of the licence agreement includes a payment of cash worth of US\$350,000 which has been paid in the year ending 30 June 2022. The group has also incurred liabilities contingent on future events in respect of the licence, which are summarised below.

Management has determined the fair value of contingent consideration by assessing the probability of each milestone being achieved. Management's assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters.

The fair value is discounted as set out in note 5(b)(iv). The timeframe for discounting varies depending on the milestone, and is aligned with industry information on the length of time taken to conduct oncological clinical trials.

- **Development Milestone Payments:** Up to US\$59.825m payable in cash and either an additional US\$5m or US\$2m in relation to milestone 5 to University of Pennsylvania upon meeting various milestones:

Milestones	Requirements	Payment to University of Pennsylvania
1.	Initiation (FPFD) of the first Phase I or Phase I/II trial (but not both)	US\$0.2m
2.	Initiation (FPFD) of the first Phase II or Phase III trial (but not both)	US\$0.875m
3.	First Commercial Sale of a CAR Licensed Product in the US	US\$10m
4.	First Commercial Sale of a CAR Licensed Product in the EU	US\$6.25m
5.	First Commercial Sale of a CAR Licensed Product in Japan	US\$5m if there is a Valid Claim in Japan or US\$2M if there is no Valid Claim in Japan but prong (d) of the Product definition applies
6.	Cumulative worldwide Net Sales in a calendar year of the first CAR Licensed Product reach \$250 million	US\$7.5m
7.	Cumulative worldwide Net Sales in a calendar year of the first CAR Licensed Product reach \$500 million	US\$15m
8.	Cumulative worldwide Net Sales in a calendar year of the first CAR Licensed Product reach \$1 billion	US\$20m

As at 30 June 2023 none of the above milestones have been achieved or paid (30 June 2022: none).

(i) Royalties on net sales

The group is obliged to pay University of Pennsylvania royalties on net sales based on industry standard single digit royalty rates. This has had no effect on the figures reported as at 30 June 2023 (30 June 2022 none.)

6 Contingent consideration (continued)

(c) CORE-NK intellectual property

The group has the licence agreement with Case Western Reserve University. The key financial terms of the licence agreement includes a payment of cash worth US\$75,000 which has been paid and issued in the year ending 30 June 2022. The group has also incurred liabilities contingent on future events in respect of the licence, which are summarised below.

Management has determined the fair value of contingent consideration by assessing the probability of each milestone being achieved. Management's assessment of the probability is based on their experience and considering industry information on clinical trial success rates and related parameters.

The fair value is discounted as set out in note 5(b)(iv). The timeframe for discounting varies depending on the milestone, and is aligned with industry information on the length of time taken to conduct oncological clinical trials.

- **Development Milestone Payments:** Up to US\$2.11m payable to Case Western Reserve University upon meeting various milestones:

Milestones	Requirements	Payable to Case Western Reserve University
1.	Completion of first in vivo animal study	US\$10k
2.	First IND Clearance	US\$50k
3.	Initiate first Phase I Clinical Trial of a Licenced Product	US\$100k
4.	Initiate first Ph II/III (registration-enabling study) Clinical Trial of a Licenced Product	US\$200k
5.	Submission of first BLA to US FDA	US\$250k
6.	First Regulatory Approval of a Licenced Product	US\$500k
7.	First Commercial Sale	US\$1m

As at 30 June 2023 none of the above milestones have been achieved or paid (30 June 2022: none).

7 Commitments

(a) Research and development commitments

(i) CAR-T technology intellectual property

Under the Licence Agreement, a non-refundable annual licence fee is payable to the City of Hope of US\$150,000. This is payable on or before 31 July of each Licence Year (excluding the first and second Licence Years ending 31 December 2020 and 31 December 2021, respectively). This fee is perpetual and US\$150,000 is recorded as an expense in the statement of comprehensive income for the current year.

(ii) CDH17 intellectual property

Under the Licence Agreement, a non refundable annual licence fee is payable to University of Pennsylvania of US\$20,000. This is payable beginning on the first anniversary of the effective date (21 July 2021) and payable annually until Licensee's payment of royalties or upon termination of the Agreement. US\$20,000 is recorded as an expense in the statement of comprehensive income for the current year.

(iii) CORE-NK intellectual property

Under the Licence Agreement, a non refundable annual licence fee is payable to Case Western Reserve University of U\$10,000. This is payable beginning on the second anniversary of the effective date (17 November 2022) and payable annually until Licensee's payment of royalties or upon termination of the Agreement. No amount has been recorded as an expense in the statement of comprehensive income for the current year.

8 Events occurring after the reporting year

On 16 August 2023, Imugene Limited (a related party of the group) entered into definitive documentation with Precision Biosciences, Inc. in relation to the research and development of the azer-cel CAR T technology.

Upon the entry into definitive documentation, Imugene Limited was obliged to pay the group an introduction fee of US\$3 million by way of cash payment. This payment was received on 23 August 2023.

No other matter or circumstance has occurred subsequent to year end that has significantly affected, or may significantly affect, the operations of the group, the results of those operations or the state of affairs of the group or economic entity in subsequent financial years.

9 Share-based payments

(a) Employee Option Plan and other share options

The establishment of the Omnibus Incentive Plan (OIP) was approved by shareholders at the annual general meeting held on 22 November 2021, and was subject to shareholder approval at the 2022 annual general meeting. The plan is designed to provide long-term incentives for employees (including directors) to deliver long-term shareholder returns. Participation in the plan is at the board's discretion and no individual has a contractual right to participate in the plan or to receive any guaranteed benefits.

The options vesting conditions are based on the achievement of service milestones, which are achieved if the holder remains with the group until the date is reached. There are no performance based milestones attached to any of the below options.

Set out below are summaries of all listed and unlisted options, issued under OIP:

	2023		2022	
	Average exercise price per share option	Number of options	Average exercise price per share option	Number of options
As at 1 July	\$0.26	27,351,537	\$0.22	21,505,556
Granted during the year	\$0.10	28,613,089	\$0.30	14,199,821
Exercised during the year	-	-	\$0.26	(49,772)
Forfeited during the year	-	-	\$0.22	(8,304,068)
As at 30 June	\$0.18	55,964,626	\$0.26	27,351,537
Vested and exercisable at 30 June	\$0.25	18,352,464	\$0.25	9,122,061

9 Share-based payments (continued)

(a) Employee Option Plan and other share options (continued)

Share options issued under OIP outstanding at the end of the year have the following expiry date and exercise prices:

Grant date	Expiry date	Exercise price (\$)	Share options 30 June 2023	Share options 30 June 2022
2020-08-28	2025-01-18	0.20	5,500,000	5,500,000
2020-11-30	2026-01-18	0.20	6,280,002	6,280,002
2021-02-01	2025-01-18	0.32	2,750,000	2,750,000
2021-03-08	2026-03-08	0.29	695,552	695,552
2021-07-01	2026-07-01	0.29	700,000	700,000
2021-07-05	2025-12-03	0.37	2,750,000	2,750,000
2021-08-27	2026-08-27	0.29	2,241,378	2,241,378
2021-08-27	2026-08-27	0.32	1,000,000	1,000,000
2021-11-22	2026-11-22	0.34	2,000,000	2,000,000
2021-11-29	2027-11-29	0.26	101,314	101,314
2021-11-29	2028-11-29	0.26	101,314	101,314
2021-11-29	2029-11-29	0.26	101,345	101,345
2021-12-22	2025-12-22	0.26	400,000	400,000
2022-01-01	2027-01-01	0.23	2,000,000	2,000,000
2022-01-25	2028-07-31	0.26	237,770	237,770
2022-01-25	2029-01-31	0.26	237,698	237,698
2022-01-25	2030-01-31	0.26	237,698	237,698
2022-01-26	2028-09-07	0.15	67,238	67,238
2022-07-01	2027-07-01	0.09	7,681,946	-
2022-08-22	2027-08-22	0.19	433,899	-
2022-10-17	2028-10-31	0.09	274,876	-
2022-11-18	2027-07-01	0.09	17,222,368	-
Total			53,014,398	27,401,309

The following options were granted outside of the OIP plan, vesting immediately upon issue. The outstanding balance at the end of the year is detailed below:

Grant date	Expiry date	Exercise price (\$)	Share options 30 June 2023	Share options 30 June 2022
2021-01-18	2024-01-18	0.30	4,957,897	4,957,897
2022-03-25	2024-03-31	0.26	83,020,927	83,020,927
2022-06-09	2024-03-31	0.26	15,000,000	15,000,000
2023-06-29	2026-07-12	0.10	4,500,000	-
2023-06-22	2027-08-18	0.46	41,891,892	-
Total			149,370,716	102,978,824

Weighted average remaining contractual life of options outstanding at end of year

3.32

2.16

9 Share-based payments (continued)

(a) Employee Option Plan and other share options (continued)

(i) Fair value of options granted

The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions.

The model inputs for options granted during the year ended 30 June 2023 included:

Grant date	Expiry date	Exercise price (\$)	No. of options	Share price at grant date (\$)	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date (\$)
2022-07-01	2027-07-01	0.092	7,681,946	0.096	100%	0.00%	3.24%	591,507
2022-07-18	2027-07-18	0.160	2,000,000	0.130	100%	0.00%	3.21%	189,799
2022-08-22	2027-08-22	0.186	433,899	0.120	100%	0.00%	3.31%	36,274
2022-08-27	2027-08-27	0.121	1,000,000	0.120	100%	0.00%	3.34%	90,999
2022-10-18	2028-10-31	0.085	274,876	0.082	100%	0.00%	3.60%	17,400
2022-11-18	2027-07-01	0.092	17,222,368	0.087	100%	0.00%	3.21%	1,143,564
2023-06-22	2028-06-22	0.046	41,891,892	0.038	64%	0.00%	3.92%	681,581
			70,504,981					

(b) Expenses arising from share-based payment transactions

Total expenses arising from share-based payment transactions recognised during the year were as follows:

	2023	2022
	\$	\$
Options issued under employee option plan	2,331,933	2,245,027

10 Remuneration of auditors

During the year the following fees were paid or payable for services provided by the auditor of the parent entity, its related practices and non-related audit firms:

(a) Grant Thornton Audit Pty Ltd

(i) Audit and other assurance services

	2023	2022
	\$	\$
Audit and review of financial statements	363,100	87,230
Total remuneration for audit and other assurance services	363,100	87,230

(ii) Taxation services

Tax compliance services	27,828	21,164
Total remuneration for taxation services	27,828	21,164

Total auditors' remuneration	390,928	108,394
-------------------------------------	----------------	---------

11 Loss per share

(a) Reconciliations of earnings used in calculating loss per share

	30 June	30 June
	2023	2022
	\$	\$
<i>Basic and diluted loss per share</i>		
Loss attributable to the ordinary equity holders of the group used in calculating loss per share:		
From continuing operations	25,500,384	15,898,400

(b) Weighted average number of shares used as the denominator

	2023	2022
	Number	Number
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	433,244,540	359,932,442

On the basis of the group's losses, the outstanding options as at 30 June 2023 are considered to be anti-dilutive and therefore were excluded from the diluted weighted average number of ordinary shares calculation.

12 Interests in other entities

(a) Subsidiaries

The group's subsidiaries at 30 June 2023 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.

Name of entity	Place of business/ country of incorporation	Ownership interest held by the group	
		2023 %	2022 %
Chimeric Therapeutics Inc	United States	100	100



Phone +61 3 98245254
Email info@chimerictherapeutics.com

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

